Biotech Values

[DewDiligence]

DPRX is trying to get Locilex approved for diabetic foot ulcers:

http://www.lifescienceleader.com/doc/does-a-full-room-at-bio-ceo-indicate-a-company-past-its-tipping-point-0001

Yes, this is the same Locilex that was rejected by FDA and almost forced Genaera into bankruptcy in 2002 (until GENR changed stripes and became an AMD/cancer company with Squalamine). DPRX says there was never any problem with the drug, but rather with the manufacturing, which has now allegedly been fixed.

Sometimes, retread programs actually work out. Among the stocks I own, CNAT is attempting such a comeback story. However, I wouldn't make a habit of investing in these kinds of programs.